14,842 Johnson & Johnson $JNJ Shares Bought by Novem Group

Key Points

• Novem Group increased its Johnson & Johnson stake by 187.7% in the third quarter, purchasing 14,842 additional shares and bringing its holdings to 22,748 shares valued at approximately $6.02 million.
• Institutional investors remain heavily involved, owning 69.55% of J&J’s outstanding stock; Wellington Management, Deutsche Bank, Amundi and Janus Henderson also increased their positions.
• J&J reported quarterly EPS of $2.59, beating estimates, while analysts maintain a consensus “Moderate Buy” rating with a $275.92 price target. The company also declared a quarterly dividend of $1.34 per share, equivalent to a 2.1% yield.

Novem Group boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 187.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,748 shares of the company's stock after buying an additional 14,842 shares during the period. Novem Group's holdings in Johnson & Johnson were worth $6,022,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its position in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Amundi boosted its position in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company's stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC boosted its position in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock valued at $1,924,323,000 after purchasing an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $1,967,399,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on JNJ. Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. HSBC raised their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a report on Thursday, September 10th. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a research report on Tuesday. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $259.42 on Wednesday. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The company has a market cap of $625.17 billion, a PE ratio of 39.31, a P/E/G ratio of 2.51 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business has a 50-day simple moving average of $265.53 and a two-hundred day simple moving average of $249.84.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The company's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: MedTech launch supports growth: J&J introduced the next-generation Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter in the U.S. The device delivers pulses at 2 Hz and is designed to reduce treatment time for calcified coronary lesions, potentially improving physician adoption and strengthening J&J’s cardiovascular portfolio. J&J launches Shockwave C2 Aero Fly catheter
• Positive Sentiment: Pipeline data remains constructive: TREMFYA maintained or improved remission in Crohn’s disease patients with perianal fistulas through 48 weeks, supporting the drug’s potential expansion and helping offset concerns about future competition to older products. J&J TREMFYA Crohn’s disease data
• Positive Sentiment: Supportive analyst view: TD Cowen reiterated a Buy rating and $300 price target, citing underappreciated pharmaceutical and MedTech growth. J&J’s latest quarterly results also exceeded EPS and revenue expectations, providing a favorable earnings backdrop.
• Neutral Sentiment: Acquisition strategy under review: Analysts see growing sales from acquired heart technologies and a larger hospital network, but competition, development costs and the need to convert revenue growth into stronger ownership returns remain concerns. J&J medical device deals analysis
• Negative Sentiment: Competitive and valuation risks: Rapport reported positive Phase II results for a novel oral bipolar drug licensed from J&J, potentially creating a future competitor to J&J’s Caplyta. Separately, JLPascual downgraded J&J to Sell, while commentary highlights that the stock trades at a premium multiple and must sustain earnings growth to justify it.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.